News in brief: Eisai and Pfizer to challenge NICE

Pharmaceutical firms Eisai and Pfizer, the co-promoters of the drug Aricept, have been granted permission by the High Court to proceed to a judicial review against NICE. They hope to challenge the process by which NICE reached its decision to disallow treatment of newly-diagnosed mild Alzheimer’s disease. The challenge is based on the grounds that NICE has refused to disclose its cost- effectiveness model for treatment of patients with Alzheimer’s disease, and that NICE has acted in an irrational and discriminatory fashion. No date has yet been set for the judicial review.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in